Nowadays, drug-resistant tuberculosis (DR-TB) and co-infected tuberculosis (CI-TB) strains
are the leading cause for the enhancement of long-term morbidity and unpredicted mortality …

Lengthy, antimicrobial therapy targeting the pathogen is the mainstay of conventional
tuberculosis treatment, complicated by emerging drug resistances. Host-directed therapies …

Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis.
However, we lack well-validated, high-throughput in vitro models that predict animal …

Introduction Tuberculosis (TB) remains one of the world's deadliest communicable diseases.
Although cure rates of the standard four-drug (rifampicin, isoniazid, pyrazinamide …

Indole-containing small molecules have been reported to have diverse pharmacological
activities. The aromatic heterocyclic scaffold, which resembles various protein structures …

Human tuberculosis (TB) is primarily caused by Mycobacterium tuberculosis (Mtb) that
inhabits inside and amidst immune cells of the host with adapted physiology to regulate …

New heterocyclic analogues of the potent biphenyl class derived from antitubercular drug
PA-824 were prepared, aiming to improve aqueous solubility but maintain high metabolic …

Stewart Cole and colleagues determined the complete genome sequence of Mycobacterium
tuberculosis (Mtb), the etiological agent of tuberculosis (TB), in 1998. This was a landmark …

Background Among the various forms of TB, tuberculous meningitis (TBM) is the most
severe, with about 30% mortality and 50% of survivors left with neurological sequelae …

Variable exposure to antituberculosis (TB) drugs, partially driven by genetic factors, may be
associated with poor clinical outcomes. Previous studies have suggested an influence of the …